Clinical trial NCT05829616: A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors
Official title: A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Initial Antitumor Activity of QLS12004 in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Advanced Solid Tumor
Lead sponsor: Qilu Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-04-25
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.

Detailed description: This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.The frequency of administration and the dose to be administered in subsequent clinical studies will be determined based on a combination of preliminary data.

Eligibility criteria: Inclusion Criteria:

1. Volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (ICF);
2. Age ≥ 18 years when ICF is signed;
3. At least one target lesion as defined per RECIST Version (v) 1.1;
4. Dose escalation phase: Pts with histologically or cytologically confirmed advanced solid tumors, who have failed standard therapy or for whom no standard therapy is available;
5. Dose escalation phase: HR+/HER2-advanced breast cancer that has failed prior CDK4/6 inhibitor combined with endocrine therapy;
6. Eastern Cooperative Oncology Group performance status of 0 or 1;
7. Adequate hematologic and organ function;
8. Female subjects who are not pregnant or breastfeeding
9. Male and female subjects able to have children must agree to use highly effective method of contraception throughout the study and for at least 90 days after last dose.

Exclusion Criteria:

1. Subjects with major cardiovascular and cerebrovascular diseases;
2. Any condition that required systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study drug;
3. Subjects who have received chemotherapy, endocrine therapy, immunotherapy, and targeted therapy, other anti-tumor treatments, or participating in other clinical studies is less than 4 weeks before the first administration of investigational product;
4. Known psychiatric or substance abuse disorders that would interfere with the requirements of the study;
5. HIV-positive or syphilis spiral antibody-positive persons;
6. Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks prior to the first dose, or the need for elective surgery during the trial;
7. Known hypersensitivity to the test drug or any of its excipients;
8. History or current evidence of any condition, therapy, or laboratory abnormality, that might confound the results of the trial, or interfere with the participant's participation for the full duration of the study, or investigators/sponsor consider the subjects are not suitable for this trial.

Primary outcomes:
measure: AEs, TEAEs, TRAEs, SAEs
timeFrame: up to 2 years
measure: DLT
timeFrame: Up to 21 days after the first dose
measure: MTD
timeFrame: Up to 21 days after the first dose
measure: RP2D
timeFrame: Up to 21 days after the first dose
Secondary outcomes:
measure: Tmax
timeFrame: up to 2 years
measure: Cmax
timeFrame: up to 2 years
measure: ORR
timeFrame: up to 2 years
measure: DCR
timeFrame: up to 2 years
measure: PFS
timeFrame: up to 2 years
measure: OS
timeFrame: up to 2 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army
state: Beijing
Study officials:
References: